CAR T Cells, FOXO3 Silencing, Washington University, Cancer Treatment
Summary
CAR T Cells, FOXO3 Silencing, Washington University, Cancer Treatment
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CAR T CELL COMPOSITIONS FOR TREATMENT OF CANCER
Application US20260108604A1 Kind: A1 Apr 23, 2026
Assignee
Washington University
Inventors
Nathan SINGH
Abstract
Compositions for the treatment of cancer that include CAR T cells in which expression of FOXO3 expression is silenced are disclosed in various aspects. In various other aspects, methods for preventing or delaying a development of dysfunction in a CAR T cell associated with chronic antigen stimulation are described that include silencing the expression of FOXO3 by the CAR T cell.
CPC Classifications
A61K 40/11 A61K 40/31 A61K 40/4212 A61P 35/00 C07K 16/2803 C12N 9/226 C12N 15/11 C12N 15/907 A61K 2239/22 C12N 2310/20
Filing Date
2023-09-15
Application No.
19111411
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.